Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

NewsBreak: Low Levels of Carcinogen Found in Heartburn Drug Zantac

Published 09/13/2019, 10:02 AM
Updated 09/13/2019, 10:28 AM
© Reuters.

© Reuters.

Investing.com - U.S. and European health officials are investigating big-selling heartburn treatment Zantac and generics of the drug after a carcinogen was discovered in low levels, Bloomberg first reported Friday.

  • The drug ranitidine, branded as Zantac, was found to contain levels of a probable carcinogen in testing by an online pharmacy. The same contaminant prompted a recall of blood-pressure pills last year.

  • "The FDA is evaluating whether the low levels of (the contaminant) NDMA in ranitidine pose a risk to patients," the regulator said. It added that it is not recommending patients stop taking the medication at this time.

  • Sanofi (PA:SASY), the maker of Zantac, fell 0.8% in Paris trading. Its ADRs (NASDAQ:SNY) lost 0.3%.
  • Latest comments

    Don't have money on it but now I need to talk to my doctor
    Theres carcinogen in vaccines but nobody cares
    Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
    Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
    Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
    It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
    Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
    © 2007-2024 - Fusion Media Limited. All Rights Reserved.